Press Coverage
Sofinnova Capital
Henrijette Richter discusses R&D in plenary at WuXi Global Forum
Related Deal lead
Henrijette RichterRelated Strategy
CapitalHenrijette Richter, managing partner at Sofinnova Partners, participated in the opening plenary panel discussion at the WuXi Global Forum 2022 on January 10. Marking the 10th anniversary of the event, the panel, led by Jorge Conde, general partner at Andreessen Horowitz, took a look back at 10 years of breakthroughs that are changing the game in R&D productivity before turning their focus on the future. Henrijette joined David Berry, founder and CEO of Valo Health; Diego Miralles, CEO of Laronde, and Roger Perlmutter, chairman and CEO of Eikon Therapeutics.
View the replay here.
Related News
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®